Gilead Sciences (English Wikipedia)

"FDA encourages ongoing education of HIV PrEP treatment". U.S. Food and Drug Administration (Press release). July 1, 2019. Archived from the original on September 14, 2019. Retrieved July 12, 2020.
"FDA Approves First Treatment for COVID-19". US Food and Drug Administration. October 22, 2020. Retrieved January 27, 2022.
"FDA Takes Actions to Expand Use of Treatment for Outpatients with Mild-to-Moderate COVID-19". US Food and Drug Administration. January 21, 2022. Archived from the original on January 22, 2022. Retrieved January 26, 2022.

accessdata.fda.gov

"Drug Approval Package: Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) NDA #021752". U.S. Food and Drug Administration. January 31, 2006. Retrieved July 12, 2020.
"Remdesivir Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). Retrieved June 29, 2020.

fiercebiotech.com (Global: low place; English: 8,828^th place)

Waldron, James (May 22, 2025). "Gilead pays partner Hookipa $10M for HBV, HIV vaccines". www.fiercebiotech.com. Retrieved May 22, 2025.

fiercepharma.com (Global: low place; English: 8,921^st place)

Stanton T (December 9, 2013). "Activists pounce on $1,000-a-day price for Gilead's hep C wonder drug, Sovaldi". FiercePharma. Archived from the original on February 18, 2014. Retrieved February 22, 2014.
"Growth-hungry Gilead finally pivots from flagging hep C with $12B Kite buy". fiercepharma.com. August 28, 2017. Retrieved August 29, 2017.
Kevin Dunleavy (October 29, 2021). "Resurgent Veklury delivers Gilead $1.9B in sales and an earnings surprise". Fierce Pharma. Retrieved January 25, 2022.

fool.com (Global: 4,183^rd place; English: 2,600^th place)

Michael Douglass (March 9, 2017). "I Was Wrong About Gilead Sciences". The Motley Fool.

forbes.com (Global: 54^th place; English: 48^th place)

Moukheiber, Kerry A. Dolan Zina. "The Golden Age of Antiviral Drugs". Forbes. Retrieved December 14, 2017.
Moukheiber, Zina; Dolan, Kerry A. (October 27, 2003). "The Golden Age of Antiviral Drugs". Forbes.
"Grading Pharma in 2013". Forbes. December 31, 2013.

fortune.com (Global: 433^rd place; English: 284^th place)

"The Giving 20: The Most Generous Companies in America". Fortune. Retrieved December 14, 2017.

ft.com (Global: 210^th place; English: 157^th place)

Kazmin, Amy (April 12, 2015). "Pharma combats diversion of cheap drugs". Financial Times. Retrieved September 27, 2021.

fundinguniverse.com (Global: 1,333^rd place; English: 957^th place)

"History of Gilead Sciences, Inc. – FundingUniverse". fundinguniverse.com.

genengnews.com (Global: low place; English: 6,625^th place)

Staff, G. E. N. (July 25, 2006). "Gilead Buys Corus Pharma for $365 million". GEN - Genetic Engineering and Biotechnology News. Retrieved September 27, 2024.
"Gilead to Acquire Phenex's FXR Program for Up-to-$470M". Genetic Engineering and Biotechnology News: GEN.
"Gilead Boosts Cancer Pipeline With $65M EpiTherapeutics Buy". Genetic Engineering and Biotechnology News: GEN. May 6, 2015.

gilead.com (Global: low place; English: low place)

gilead.com

"U.S. Food And Drug Administration (FDA) Approves Atripla" (Press release). Gilead Sciences and Bristol-Myers Squibb. July 12, 2006. Archived from the original on November 15, 2008. Retrieved December 15, 2007.
"Gilead Sciences Completes Acquisition of Raylo Chemicals Inc" (Press release). Gilead Sciences. November 3, 2006. Archived from the original on January 16, 2013. Retrieved June 7, 2007.
"Parion Sciences and Gilead Sciences Sign Agreement to Advance Drug Candidates for Pulmonary Disease" (Press release). Gilead Sciences. August 15, 2007. Archived from the original on February 8, 2013. Retrieved August 15, 2007.
"Gilead Sciences to Acquire Arresto Biosciences for $225 Million; Deal Adds Pipeline Candidates for Fibrotic Diseases" (Press release). Gilead Sciences. December 20, 2010. Archived from the original on January 13, 2011. Retrieved January 15, 2011.
"Gilead Sciences to Acquire Calistoga Pharmaceuticals for $375 Million". Gilead Sciences, Inc. (Press release). February 22, 2011. Retrieved July 12, 2020.
"Gilead Sciences to Acquire Immunomedics".
"Gilead Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia". www.gilead.com. Retrieved February 7, 2022.
"Mission & Core Values – Gilead". www.gilead.com. Archived from the original on August 11, 2022. Retrieved March 27, 2019.

investors.gilead.com

"Gilead Sciences to Acquire Calistoga Pharmaceuticals for $375 Million; Deal Adds Pipeline Candidates in Oncology and Inflammation" (Press release). Gilead Sciences. February 22, 2011. Archived from the original on July 9, 2012. Retrieved February 22, 2011.
"Gilead Sciences Announces Acquisition of Nimbus Therapeutics' Acetyl-CoA Carboxylase (ACC) Program for NASH and Other Liver Diseases | Gilead Sciences". investors.gilead.com. Archived from the original on September 23, 2021. Retrieved September 23, 2021.
"Gilead Completes Acquisition of Forty Seven, Inc". Gilead Sciences. Archived from the original on April 25, 2022. Retrieved April 11, 2020.
"Gilead Sciences, Inc. 2019 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. Gilead Sciences. February 2020. Archived from the original (PDF) on March 13, 2022. Retrieved April 19, 2020.

handle.net (Global: 102^nd place; English: 76^th place)

hdl.handle.net

Lamontagne F, Agoritsas T, Macdonald H, Leo YS, et al. (September 2020). "A living WHO guideline on drugs for covid-19". BMJ. 370 m3379. doi:10.1136/bmj.m3379. hdl:2429/78756. PMID 32887691. S2CID 221498813.

healio.com (Global: low place; English: low place)

"FDA approves first generic of Tamiflu for influenza A, B". www.healio.com. August 4, 2016. Retrieved April 3, 2020.

icer.org (Global: low place; English: low place)

"Institute for Clinical and Economic Review Announces Most Significant Drug-Price Hikes Unsupported by New Clinical Evidence in US". ICER. Retrieved February 6, 2025.

independent.co.uk (Global: 36^th place; English: 33^rd place)

"Donald Rumsfeld makes $5m killing on bird flu drug". The Independent. March 12, 2006. Retrieved August 2, 2020.

investors.com (Global: low place; English: 6,516^th place)

Allison Gatlin (April 6, 2017). "Will Gilead's HIV Franchise Plan Be Dashed On TrumpCare?". Investor's Business Daily. Investors Business Daily.

jennerlawfirm.com (Global: low place; English: low place)

Jenner, Rob (January 12, 2024). ""Morally Blameworthy" Gilead Under Fire in Legal Battle Over HIV Medication". Jenner Law, Baltimore MD. Retrieved January 12, 2024.

ktvq.com (Global: low place; English: low place)

"Donald Rumsfeld Fast Facts". KTVQ. June 27, 2019. Retrieved April 3, 2020.

latimes.com (Global: 22^nd place; English: 19^th place)

Gellene, Denise (December 5, 2002). "Gilead Sciences to Buy Triangle Pharmaceuticals". Los Angeles Times.
Petersen, Melody (May 5, 2018). "Patients sue Gilead, saying drug company intentionally delayed safer HIV medicine". Los Angeles Times. Retrieved December 7, 2019.
Petersen, Melody (May 9, 2018). "Patients sue Gilead, saying drug company intentionally delayed safer HIV medicine". Los Angeles Times. Retrieved March 11, 2022.

lexpert.ca (Global: low place; English: low place)

"Gilead Sciences Acquires YM Biosciences". www.lexpert.ca. Retrieved October 23, 2024.

macrotrends.net (Global: 5,641^st place; English: 4,405^th place)

"Gilead Sciences Revenue 2006–2018". www.macrotrends.net. Retrieved November 1, 2018.

msf.org (Global: low place; English: low place)

"No profiteering on COVID-19 drugs and vaccines, says MSF". Médecins Sans Frontières (MSF) International.

msn.com (Global: 117^th place; English: 145^th place)

today.msnbc.msn.com

Perrone, Matthew (July 16, 2012). "FDA approves first pill to help prevent HIV". Today Health. NBC News. Archived from the original on July 16, 2012. Retrieved July 16, 2012.

nbcnews.com (Global: 137^th place; English: 101^st place)

Fitzsimmons, Tim (July 19, 2018). "#BreakThePatent: How HIV activists are going after Gilead's PrEP patent". NBC News. Retrieved September 19, 2021.
Ryan, Benjamin (July 7, 2021). "Pharma giant's policy change will devastate local HIV-prevention clinics' efforts". NBC News. Retrieved September 23, 2021.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Masho, Saba Woldemichael; Wang, Cun-Lin; Nixon, Daniel E (December 2007). "Review of tenofovir-emtricitabine". Therapeutics and Clinical Risk Management. 3 (6): 1097–1104. ISSN 1176-6336. PMC 2387297. PMID 18516268.
Keating GM (2015). "Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C". Drugs. 75 (6): 675–85. doi:10.1007/s40265-015-0381-2. PMID 25837989. S2CID 31943736.
Tourret, Jérôme; Deray, Gilbert; Isnard-Bagnis, Corinne (2013). "Tenofovir Effect on the Kidneys of HIV-Infected Patients: A Double-Edged Sword?". Journal of the American Society of Nephrology. 24 (10): 1519–1527. doi:10.1681/ASN.2012080857. PMC 3785270. PMID 24052632.
Grigsby, Iwen F.; Pham, Lan; Mansky, Louis M.; Gopalakrishnan, Raj; Mansky, Kim C. (2010). "Tenofovir-associated bone density loss". Therapeutics and Clinical Risk Management. 6: 41–47. PMC 2817787. PMID 20169035.
Walensky, Rochelle P.; Horn, Tim; McCann, Nicole C.; Freedberg, Kenneth A.; Paltiel, A. David (May 5, 2020). "Comparative Pricing of Branded Tenofovir Alafenamide–Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate–Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis". Annals of Internal Medicine. 172 (9): 583–590. doi:10.7326/m19-3478. PMC 7217721. PMID 32150602.
Rizk, John G.; Forthal, Donald N.; Kalantar-Zadeh, Kamyar; Mehra, Mandeep R.; Lavie, Carl J.; Rizk, Youssef; Pfeiffer, JoAnn P.; Lewin, John C. (2021). "Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic". Drug Discovery Today. 26 (2): 593–603. doi:10.1016/j.drudis.2020.11.025. ISSN 1359-6446. PMC 7694556. PMID 33253920.
Lamontagne F, Agoritsas T, Macdonald H, Leo YS, et al. (September 2020). "A living WHO guideline on drugs for covid-19". BMJ. 370 m3379. doi:10.1136/bmj.m3379. hdl:2429/78756. PMID 32887691. S2CID 221498813.
Ali K, Azher T, Baqi M, Binnie A, et al. (January 2022). "Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial". Canadian Medical Association Journal. 194 (7): E242 – E251. doi:10.1503/cmaj.211698. PMC 8863204. PMID 35045989.

ncbi.nlm.nih.gov

Masho, Saba Woldemichael; Wang, Cun-Lin; Nixon, Daniel E (December 2007). "Review of tenofovir-emtricitabine". Therapeutics and Clinical Risk Management. 3 (6): 1097–1104. ISSN 1176-6336. PMC 2387297. PMID 18516268.
Tourret, Jérôme; Deray, Gilbert; Isnard-Bagnis, Corinne (2013). "Tenofovir Effect on the Kidneys of HIV-Infected Patients: A Double-Edged Sword?". Journal of the American Society of Nephrology. 24 (10): 1519–1527. doi:10.1681/ASN.2012080857. PMC 3785270. PMID 24052632.
Grigsby, Iwen F.; Pham, Lan; Mansky, Louis M.; Gopalakrishnan, Raj; Mansky, Kim C. (2010). "Tenofovir-associated bone density loss". Therapeutics and Clinical Risk Management. 6: 41–47. PMC 2817787. PMID 20169035.
Walensky, Rochelle P.; Horn, Tim; McCann, Nicole C.; Freedberg, Kenneth A.; Paltiel, A. David (May 5, 2020). "Comparative Pricing of Branded Tenofovir Alafenamide–Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate–Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis". Annals of Internal Medicine. 172 (9): 583–590. doi:10.7326/m19-3478. PMC 7217721. PMID 32150602.
Rizk, John G.; Forthal, Donald N.; Kalantar-Zadeh, Kamyar; Mehra, Mandeep R.; Lavie, Carl J.; Rizk, Youssef; Pfeiffer, JoAnn P.; Lewin, John C. (2021). "Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic". Drug Discovery Today. 26 (2): 593–603. doi:10.1016/j.drudis.2020.11.025. ISSN 1359-6446. PMC 7694556. PMID 33253920.
Ali K, Azher T, Baqi M, Binnie A, et al. (January 2022). "Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial". Canadian Medical Association Journal. 194 (7): E242 – E251. doi:10.1503/cmaj.211698. PMC 8863204. PMID 35045989.

nih.gov

"Harold E. Varmus, M.D." National Institutes of Health (NIH). August 6, 2015. Retrieved February 25, 2019.

aidsinfo.nih.gov

"FDA approves first drug for reducing the risk of sexually acquired HIV infection" (Press release). July 16, 2012. Archived from the original on December 12, 2017. Retrieved July 12, 2020.

npr.org (Global: 92^nd place; English: 72^nd place)

Simmons-Duffin, Selena (May 30, 2019). "AIDS Activists Take Aim At Gilead To Lower Price Of HIV Drug PrEP". NPR. Retrieved September 19, 2021.
Lupkin, Sydney (March 24, 2020). "FDA Grants Experimental Coronavirus Drug Benefits For Rare Disease Treatments". NPR. Retrieved March 24, 2020.

nytimes.com (Global: 7^th place; English: 7^th place)

Fisher, Lawrence M. (June 28, 1996). "F.D.A. Approves Gilead's Drug for AIDS Patients". The New York Times. ISSN 0362-4331. Retrieved September 22, 2021.
McFadden, Robert D. (June 30, 2021). "Donald H. Rumsfeld, Defense Secretary During Iraq War, Is Dead at 88". The New York Times. Retrieved October 23, 2024.
Pollack, Andrew (July 13, 2006). "F.D.A. Backs AIDS Pill to Be Taken Once a Day". The New York Times. Retrieved September 20, 2007.
"Gilead to Buy CV Therapeutics for $1.4 Billion". The New York Times. Reuters. March 12, 2009. Retrieved April 25, 2020.
McNeil, Jr., Donald G. (May 9, 2019). "Gilead Will Donate Truvada to U.S. for H.I.V. Prevention". The New York Times. ISSN 0362-4331. Retrieved December 4, 2019.
McNeil, Jr., Donald G. (December 3, 2019). "200,000 Uninsured Americans to Get Free H.I.V.-Prevention Drugs". The New York Times. ISSN 0362-4331. Retrieved December 4, 2019.
Sanger-Katz, Margot (August 2, 2014). "Critics Raise Concerns About Sovaldi". The New York Times. ISSN 0362-4331. Retrieved October 4, 2015.
McNeil, Donald G. (May 10, 2019). "Gilead Will Donate Truvada to U.S. for H.I.V. Prevention". The New York Times. Retrieved September 20, 2021.

outsourcing-pharma.com (Global: low place; English: low place)

Stanton, Dan (May 20, 2015). "Gilead's reliance on CMOs gives firm 'flexibility' says CFO". Outsourcing-Pharma.com. Crawley: William Reed Business Media Ltd. Retrieved April 1, 2020.

parentherald.com (Global: low place; English: low place)

"Gilead Sciences: Nimbus Drug Acquired, Offering Cure For Fatty Liver". Parent Herald. April 6, 2016.

pharmaceutical-technology.com (Global: low place; English: low place)

Priyan, Vishnu (September 11, 2024). "Gilead and Genesis partner to create novel therapies using AI". Pharmaceutical Technology. Retrieved September 16, 2024.
Debbarma, Salong (December 26, 2025). "Gilead Sciences to acquire Repare's RP-3467". Pharmaceutical Technology. Retrieved December 27, 2025.

pharmatimes.com (Global: low place; English: low place)

"Roche settles dispute with Gilead over Tamiflu". PharmaTimes. November 17, 2005. Retrieved September 19, 2021.

policymed.com (Global: low place; English: low place)

Sullivan, Thomas (May 5, 2018). "Senate Finance Committee Releases Results of Investigation Into Gilead's Pricing Strategy for Hepatitis-C Drugs". Policy & Medicine.

reuters.com (Global: 49^th place; English: 47^th place)

"Gilead to buy Kite for promising cancer therapies in $12 billion deal". reuters.com. August 28, 2017.
"Gilead to buy Cell Design Labs for up to $567 million". reuters.com. December 7, 2017. Archived from the original on June 6, 2020.
"Gilead buys Forty Seven for $4.9 billion to bolster cancer drug pipeline". Reuters. March 2, 2020. Archived from the original on March 27, 2022.
"Gilead to buy 49.9% stake in cancer drug developer for $275 million". Reuters. June 23, 2020 – via www.reuters.com.
"Gilead to acquire German biotech firm MYR for about 1.15 billion euros". Reuters. December 10, 2020 – via www.reuters.com.
Beasley, Deena (May 6, 2020). "Will Gilead price its coronavirus drug for public good or company profit?". Reuters. Retrieved September 19, 2021. Public outrage over the cost of Sovaldi in 2013 - despite that it was a vast improvement over existing equally expensive therapies - ignited a national debate on fair pricing for prescription medicines that the pharmaceutical industry has fought to deflect ever since.
Rapaport, Lisa (March 9, 2020). "New brand-name HIV-prevention pill not worth the added cost: study". Reuters. Retrieved September 23, 2021.

scribd.com (Global: 482^nd place; English: 552^nd place)

"Gilead Sciences Board Resolution Michael Riordan Founder CEO Chairman Antiviral Medicine AIDS Therapeutics Nucleotides". Scribd. Retrieved December 14, 2017.

sec.gov (Global: 572^nd place; English: 436^th place)

"Gilead Sciences, Inc. 2024 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. February 28, 2025.
"Gilead Sciences, Inc. 2021 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. Gilead Sciences. February 23, 2022.

seekingalpha.com (Global: 5,344^th place; English: 3,420^th place)

"Gilead Q4 2014 Earnings Call". February 3, 2015.
Ioannis Stamatopoulos (February 12, 2017). "Pharma M&A In 2017: The Most Likely Deal Hunters". Seeking Alpha. Retrieved March 12, 2017.
Dulan Lokuwithana (October 28, 2021). "Gilead lifts 2021 guidance as remdesivir sales more than double in Q3". Seeking Alpha. Retrieved January 25, 2022.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Keating GM (2015). "Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C". Drugs. 75 (6): 675–85. doi:10.1007/s40265-015-0381-2. PMID 25837989. S2CID 31943736.
Lamontagne F, Agoritsas T, Macdonald H, Leo YS, et al. (September 2020). "A living WHO guideline on drugs for covid-19". BMJ. 370 m3379. doi:10.1136/bmj.m3379. hdl:2429/78756. PMID 32887691. S2CID 221498813.

sfgate.com (Global: 166^th place; English: 121^st place)

Tansey, Bernadette (April 14, 2003). "Profile: Gilead Sciences / Gilead grows up / Visionary biotech startup matures into pragmatic industry leader". San Francisco Chronicle. Hearst Communications, Inc. p. E1. Retrieved March 21, 2020.

smh.com.au (Global: 132^nd place; English: 96^th place)

Hammond, Ed; Kirchfeld, Aaron; Nair, Dinesh (June 7, 2020). "A new pharma king? AstraZeneca approaches Gilead about potential merger: report". The Sydney Morning Herald. Retrieved June 8, 2020.

statnews.com (Global: 8,771^st place; English: 5,253^rd place)

Silverman, Ed (July 13, 2016). "Gilead avoided nearly $10 billion in taxes last year thanks to tax dodges". Stat News. Retrieved January 2, 2022.

streetinsider.com (Global: low place; English: low place)

"Q4 Sovaldi Sales Tracking at $53 Million". Street Insider. January 3, 2014.

thepharmaletter.com (Global: low place; English: low place)

"Veklury becomes first option for COVID-19 approved in EU". The Pharma Letter. March 7, 2020. Retrieved January 25, 2022.

thetimes.com (Global: low place; English: low place)

Paul O'Donoghue (December 26, 2018). "US pharma giant Gilead uses 'Double Irish' tax loophole". The Times. London.

washingtonpost.com (Global: 34^th place; English: 27^th place)

Rowland, Christopher (March 26, 2019). "An HIV treatment cost taxpayers millions. The government patented it. But a pharma giant is making billions". Washington Post.
Johnson, Carolyn Y.; Dennis, Brady (December 1, 2015). "How an $84,000 drug got its price: 'Let's hold our position … whatever the headlines'". Washington Post. Retrieved September 19, 2021.
Rowland, Christopher (May 16, 2019). "Gilead CEO insists federal government patent for HIV prevention pill Truvada is invalid". Washington Post. Retrieved September 19, 2021.
Rowland, Christopher (May 14, 2019). "Gilead is accused of cutting anti-competitive deals to extend profit on HIV drug combinations". Washington Post. Retrieved September 27, 2021.
Merle, Renae; Johnson, Carolyn Y. "The drug company that shocked the world with its prices dodged $10 billion in taxes, report says". The Washington Post. ISSN 0190-8286. Retrieved January 2, 2022.

web.archive.org (Global: 1^st place; English: 1^st place)

Stanton T (December 9, 2013). "Activists pounce on $1,000-a-day price for Gilead's hep C wonder drug, Sovaldi". FiercePharma. Archived from the original on February 18, 2014. Retrieved February 22, 2014.
"1996 Alumni Achievement Awards". Washington University in St. Louis. Archived from the original on August 21, 2014.
"U.S. Food And Drug Administration (FDA) Approves Atripla" (Press release). Gilead Sciences and Bristol-Myers Squibb. July 12, 2006. Archived from the original on November 15, 2008. Retrieved December 15, 2007.
"Gilead Sciences Completes Acquisition of Raylo Chemicals Inc" (Press release). Gilead Sciences. November 3, 2006. Archived from the original on January 16, 2013. Retrieved June 7, 2007.
"Parion Sciences and Gilead Sciences Sign Agreement to Advance Drug Candidates for Pulmonary Disease" (Press release). Gilead Sciences. August 15, 2007. Archived from the original on February 8, 2013. Retrieved August 15, 2007.
"Gilead Sciences to Acquire Arresto Biosciences for $225 Million; Deal Adds Pipeline Candidates for Fibrotic Diseases" (Press release). Gilead Sciences. December 20, 2010. Archived from the original on January 13, 2011. Retrieved January 15, 2011.
Perrone, Matthew (July 16, 2012). "FDA approves first pill to help prevent HIV". Today Health. NBC News. Archived from the original on July 16, 2012. Retrieved July 16, 2012.
"FDA encourages ongoing education of HIV PrEP treatment". U.S. Food and Drug Administration (Press release). July 1, 2019. Archived from the original on September 14, 2019. Retrieved July 12, 2020.
"FDA approves first drug for reducing the risk of sexually acquired HIV infection" (Press release). July 16, 2012. Archived from the original on December 12, 2017. Retrieved July 12, 2020.
"Gilead Sciences Announces Acquisition of Nimbus Therapeutics' Acetyl-CoA Carboxylase (ACC) Program for NASH and Other Liver Diseases | Gilead Sciences". investors.gilead.com. Archived from the original on September 23, 2021. Retrieved September 23, 2021.
"Gilead to buy Cell Design Labs for up to $567 million". reuters.com. December 7, 2017. Archived from the original on June 6, 2020.
"Gilead buys Forty Seven for $4.9 billion to bolster cancer drug pipeline". Reuters. March 2, 2020. Archived from the original on March 27, 2022.
"Gilead Completes Acquisition of Forty Seven, Inc". Gilead Sciences. Archived from the original on April 25, 2022. Retrieved April 11, 2020.
Ketaki Gokhale (December 28, 2015). "The same pill that cost $1,000 in the U.S. sold for $4 in India". Bloomberg News. Archived from the original on December 31, 2015.
"Gilead Sciences, Inc. 2019 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. Gilead Sciences. February 2020. Archived from the original (PDF) on March 13, 2022. Retrieved April 19, 2020.
"Mission & Core Values – Gilead". www.gilead.com. Archived from the original on August 11, 2022. Retrieved March 27, 2019.
Waldman R. "Gilead's HCV drug sofosbuvir approved by the FDA but accessible for how many?" (PDF). Doctors of the World. Archived from the original (PDF) on February 26, 2014. Retrieved February 22, 2014.
"FDA Takes Actions to Expand Use of Treatment for Outpatients with Mild-to-Moderate COVID-19". US Food and Drug Administration. January 21, 2022. Archived from the original on January 22, 2022. Retrieved January 26, 2022.

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

Fisher, Lawrence M. (June 28, 1996). "F.D.A. Approves Gilead's Drug for AIDS Patients". The New York Times. ISSN 0362-4331. Retrieved September 22, 2021.
Masho, Saba Woldemichael; Wang, Cun-Lin; Nixon, Daniel E (December 2007). "Review of tenofovir-emtricitabine". Therapeutics and Clinical Risk Management. 3 (6): 1097–1104. ISSN 1176-6336. PMC 2387297. PMID 18516268.
McNeil, Jr., Donald G. (May 9, 2019). "Gilead Will Donate Truvada to U.S. for H.I.V. Prevention". The New York Times. ISSN 0362-4331. Retrieved December 4, 2019.
McNeil, Jr., Donald G. (December 3, 2019). "200,000 Uninsured Americans to Get Free H.I.V.-Prevention Drugs". The New York Times. ISSN 0362-4331. Retrieved December 4, 2019.
Lombardo, Cara; Rockoff, Jonathan D. (September 13, 2020). "Gilead Reaches Deal to Buy Immunomedics for $21 Billion". Wall Street Journal. ISSN 0099-9660. Retrieved September 13, 2020.
Sanger-Katz, Margot (August 2, 2014). "Critics Raise Concerns About Sovaldi". The New York Times. ISSN 0362-4331. Retrieved October 4, 2015.
Merle, Renae; Johnson, Carolyn Y. "The drug company that shocked the world with its prices dodged $10 billion in taxes, report says". The Washington Post. ISSN 0190-8286. Retrieved January 2, 2022.
Rizk, John G.; Forthal, Donald N.; Kalantar-Zadeh, Kamyar; Mehra, Mandeep R.; Lavie, Carl J.; Rizk, Youssef; Pfeiffer, JoAnn P.; Lewin, John C. (2021). "Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic". Drug Discovery Today. 26 (2): 593–603. doi:10.1016/j.drudis.2020.11.025. ISSN 1359-6446. PMC 7694556. PMID 33253920.

wsj.com (Global: 79^th place; English: 65^th place)

Silverman, Ed (December 19, 2014). "Lawsuit Alleges Price Gouging by Maker of Hepatitis Drug". Wall Street Journal. Retrieved September 19, 2021.
Silverman, Ed (September 15, 2014). "Gilead Deal to Sell Sovaldi in Poor Countries Meets Criticism". Wall Street Journal. Retrieved September 19, 2021.
"Gilead to Pay $464 Million For Triangle Pharmaceuticals". Wall Street Journal. December 4, 2002.
Lombardo, Cara; Rockoff, Jonathan D. (September 13, 2020). "Gilead Reaches Deal to Buy Immunomedics for $21 Billion". Wall Street Journal. ISSN 0099-9660. Retrieved September 13, 2020.

wustl.edu (Global: 3,160^th place; English: 2,065^th place)

engineering.wustl.edu

"1996 Alumni Achievement Awards". Washington University in St. Louis. Archived from the original on August 21, 2014.

yahoo.com (Global: 38^th place; English: 40^th place)

finance.yahoo.com

"Gilead (GILD) Collaborates with Galapagos for Filgotinib". Yahoo Finance. Yahoo/Zack's. December 18, 2015. Retrieved December 31, 2015.

Gilead Sciences (English Wikipedia)

247wallst.com (Global: low place; English: low place)

archive.today (Global: 14th place; English: 14th place)

arizonalawreview.org (Global: low place; English: low place)

barrons.com (Global: 2,737th place; English: 1,700th place)

blogs.barrons.com

biopharmadive.com (Global: low place; English: low place)

biospace.com (Global: low place; English: 7,595th place)

bizjournals.com (Global: 407th place; English: 241st place)

bloodjournal.org (Global: low place; English: low place)

bloomberg.com (Global: 99th place; English: 77th place)

bloomberglaw.com (Global: 5,670th place; English: 3,086th place)

news.bloomberglaw.com

books.google.com (Global: 3rd place; English: 3rd place)

businesswire.com (Global: 615th place; English: 407th place)

canada.ca (Global: 1,712th place; English: 1,063rd place)

caravanmagazine.in (Global: 4,487th place; English: 2,443rd place)

chicagotribune.com (Global: 95th place; English: 70th place)

clinicaltrials.gov (Global: 5,225th place; English: 4,062nd place)

cnbc.com (Global: 220th place; English: 155th place)

cnn.com (Global: 28th place; English: 26th place)

money.cnn.com

doctorsoftheworld.org (Global: low place; English: low place)

doi.org (Global: 2nd place; English: 2nd place)

esgtoday.com (Global: low place; English: low place)

europa.eu (Global: 68th place; English: 117th place)

ema.europa.eu

fda.gov (Global: 447th place; English: 338th place)

fda.gov

accessdata.fda.gov

fiercebiotech.com (Global: low place; English: 8,828th place)

fiercepharma.com (Global: low place; English: 8,921st place)

fool.com (Global: 4,183rd place; English: 2,600th place)

forbes.com (Global: 54th place; English: 48th place)

fortune.com (Global: 433rd place; English: 284th place)

ft.com (Global: 210th place; English: 157th place)

fundinguniverse.com (Global: 1,333rd place; English: 957th place)

genengnews.com (Global: low place; English: 6,625th place)

gilead.com (Global: low place; English: low place)

gilead.com

investors.gilead.com

handle.net (Global: 102nd place; English: 76th place)

hdl.handle.net

healio.com (Global: low place; English: low place)

icer.org (Global: low place; English: low place)

independent.co.uk (Global: 36th place; English: 33rd place)

investors.com (Global: low place; English: 6,516th place)

jennerlawfirm.com (Global: low place; English: low place)

ktvq.com (Global: low place; English: low place)

latimes.com (Global: 22nd place; English: 19th place)

lexpert.ca (Global: low place; English: low place)

macrotrends.net (Global: 5,641st place; English: 4,405th place)

msf.org (Global: low place; English: low place)

msn.com (Global: 117th place; English: 145th place)

today.msnbc.msn.com

nbcnews.com (Global: 137th place; English: 101st place)

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

nih.gov

aidsinfo.nih.gov

npr.org (Global: 92nd place; English: 72nd place)

nytimes.com (Global: 7th place; English: 7th place)

outsourcing-pharma.com (Global: low place; English: low place)

parentherald.com (Global: low place; English: low place)

pharmaceutical-technology.com (Global: low place; English: low place)

pharmatimes.com (Global: low place; English: low place)

policymed.com (Global: low place; English: low place)

reuters.com (Global: 49th place; English: 47th place)

scribd.com (Global: 482nd place; English: 552nd place)

sec.gov (Global: 572nd place; English: 436th place)

seekingalpha.com (Global: 5,344th place; English: 3,420th place)

semanticscholar.org (Global: 11th place; English: 8th place)

api.semanticscholar.org

sfgate.com (Global: 166th place; English: 121st place)

smh.com.au (Global: 132nd place; English: 96th place)

statnews.com (Global: 8,771st place; English: 5,253rd place)

streetinsider.com (Global: low place; English: low place)

thepharmaletter.com (Global: low place; English: low place)

thetimes.com (Global: low place; English: low place)

archive.today (Global: 14^th place; English: 14^th place)

barrons.com (Global: 2,737^th place; English: 1,700^th place)

biospace.com (Global: low place; English: 7,595^th place)

bizjournals.com (Global: 407^th place; English: 241^st place)

bloomberg.com (Global: 99^th place; English: 77^th place)

bloomberglaw.com (Global: 5,670^th place; English: 3,086^th place)

books.google.com (Global: 3^rd place; English: 3^rd place)

businesswire.com (Global: 615^th place; English: 407^th place)

canada.ca (Global: 1,712^th place; English: 1,063^rd place)

caravanmagazine.in (Global: 4,487^th place; English: 2,443^rd place)

chicagotribune.com (Global: 95^th place; English: 70^th place)

clinicaltrials.gov (Global: 5,225^th place; English: 4,062^nd place)

cnbc.com (Global: 220^th place; English: 155^th place)

cnn.com (Global: 28^th place; English: 26^th place)

doi.org (Global: 2^nd place; English: 2^nd place)

europa.eu (Global: 68^th place; English: 117^th place)

fda.gov (Global: 447^th place; English: 338^th place)

fiercebiotech.com (Global: low place; English: 8,828^th place)

fiercepharma.com (Global: low place; English: 8,921^st place)

fool.com (Global: 4,183^rd place; English: 2,600^th place)

forbes.com (Global: 54^th place; English: 48^th place)

fortune.com (Global: 433^rd place; English: 284^th place)

ft.com (Global: 210^th place; English: 157^th place)

fundinguniverse.com (Global: 1,333^rd place; English: 957^th place)

genengnews.com (Global: low place; English: 6,625^th place)

handle.net (Global: 102^nd place; English: 76^th place)

independent.co.uk (Global: 36^th place; English: 33^rd place)

investors.com (Global: low place; English: 6,516^th place)

latimes.com (Global: 22^nd place; English: 19^th place)

macrotrends.net (Global: 5,641^st place; English: 4,405^th place)

msn.com (Global: 117^th place; English: 145^th place)

nbcnews.com (Global: 137^th place; English: 101^st place)

nih.gov (Global: 4^th place; English: 4^th place)

npr.org (Global: 92^nd place; English: 72^nd place)

nytimes.com (Global: 7^th place; English: 7^th place)

reuters.com (Global: 49^th place; English: 47^th place)

scribd.com (Global: 482^nd place; English: 552^nd place)

sec.gov (Global: 572^nd place; English: 436^th place)

seekingalpha.com (Global: 5,344^th place; English: 3,420^th place)

semanticscholar.org (Global: 11^th place; English: 8^th place)

sfgate.com (Global: 166^th place; English: 121^st place)

smh.com.au (Global: 132^nd place; English: 96^th place)

statnews.com (Global: 8,771^st place; English: 5,253^rd place)

washingtonpost.com (Global: 34^th place; English: 27^th place)

web.archive.org (Global: 1^st place; English: 1^st place)

worldcat.org (Global: 5^th place; English: 5^th place)

wsj.com (Global: 79^th place; English: 65^th place)

wustl.edu (Global: 3,160^th place; English: 2,065^th place)

yahoo.com (Global: 38^th place; English: 40^th place)